D. Chaplin

J. Overgaard, M. Horsman, D. Chaplin, 1996, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Early spatial and temporal changes in tumour perfusion after administration of flavone acetic acid.

M. Trotter, D. Chaplin, C. Peters, 1991, International journal of radiation biology.

The effect of combining flavone acetic acid and hyperthermia on the growth of a C3H mammary carcinoma in vivo.

J. Overgaard, M. Horsman, D. Chaplin, 1991, International Journal of Radiation Biology.

Ischaemia induced cell death in tumors: importance of temperature and pH.

M. Horsman, D. Chaplin, S. Hill, 1994, International journal of radiation oncology, biology, physics.

Spatial characterization of glutathione depletion in the KHT sarcoma using flow cytometry.

D. Chaplin, A. Minchinton, 1991, International journal of radiation biology.

Histological evidence for nonperfused vasculature in a murine tumor following hydralazine administration.

M. Trotter, D. Chaplin, B. Acker, 1989, International journal of radiation oncology, biology, physics.

Multiple mechanisms of action of the benzamides and nicotinamides as sensitizers of radiotherapy: opportunities for drug design.

R. Pero, A. Olsson, D. Chaplin, 1998, Cancer detection and prevention.

MICROREGIONAL HETEROGENEITY IN TUMOUR PERFUSION

M. Trotter, D. Chaplin, 1992 .

Blood flow modification in the SCCVII tumor: effects of 5-hydroxytryptamine, hydralazine, and propranolol.

D. Chaplin, C. Peters, 1992, International journal of radiation oncology, biology, physics.

Drug induced perturbations in tumor blood flow: therapeutic potential and possible limitations.

M. Trotter, M. Horsman, D. Chaplin, 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse.

M. Trotter, D. Chaplin, P. Olive, 1990, British Journal of Cancer.

Modification of tumour radiation response in vivo by the benzamide analogue pyrazinamide.

M. Trotter, M. Horsman, D. Chaplin, 1990, British Journal of Cancer.

Tumour Blood Flow and Its Modulation: Implications for Bioreductive Drug Activity in vivo

M. Trotter, M. Horsman, D. Chaplin, 1990 .

Postirradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers.

D. Chaplin, 1988, Radiation research.

MRS studies of cancer

F. Howe, J. Griffiths, S. Howells, 1994, Magnetic Resonance Materials in Physics, Biology and Medicine.

The radiation response of KHT sarcomas following nicotinamide treatment and carbogen breathing.

M. Horsman, D. Chaplin, D. Siemann, 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The combination of nicotinamide and carbogen breathing to improve tumour oxygenation prior to radiation treatment.

J. Overgaard, M. Horsman, A. Khalil, 1994, Advances in experimental medicine and biology.

Chemosensitization by misonidazole in CCNU-treated spheroids and tumours.

D. Chaplin, R. Durand, DJ Chaplin, 1987, British Journal of Cancer.

The effect of low pH and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitro.

L. Skarsgard, D. Chaplin, M. Skwarchuk, 1994, International journal of radiation oncology, biology, physics.

Exaggerated hypertensive response to combretastatin A-4 phosphate in hypertensive rats: Effective pharmacological inhibition by diltiazem.

P. Kang, M. Samad, D. Chaplin, 2015, Vascular pharmacology.

Potentiation of cyclophosphamide cytotoxicity in vivo: a study with misonidazole and fifteen other 1-substituted 2-nitroimidazoles.

G. Adams, D. Chaplin, P. Sheldon, 1984, International journal of radiation oncology, biology, physics.

Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L.

M. Horsman, D. Chaplin, M. L. Trawick, 2012, European journal of medicinal chemistry.

Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours.

D. Chaplin, P. Olive, R. Durand, 1985, British Journal of Cancer.

c Measurement of Tumor Oxygenation PRECLINICAL EVALUATION OF THE NOVEL HYPOXIC MARKER 99m Tc-HL91 (PROGNOX) IN MURINE AND XENOGRAFT SYSTEMS IN VIVO

D. Chaplin, S. Hill, D. Honess, 1998 .

Proportion of infiltrating IgG-binding immune cells predict for tumour hypoxia

D. Chaplin, S. Hill, D. Collingridge, 2001, British Journal of Cancer.

Acute hypoxia in tumors: implications for modifiers of radiation effects.

D. Chaplin, R E Durand, P. Olive, 1986, International journal of radiation oncology, biology, physics.

Enhancement of cyclophosphamide cytotoxicity in vivo by the benzamide analogue pyrazinamide.

M. Horsman, D. Chaplin, D. Chaplin, 1994, British Journal of Cancer.

The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells.

L. Skarsgard, D. Chaplin, M. Skwarchuk, 1993, British Journal of Cancer.

Effects Intermittent Blood Flow in a Murine Tumor : Radiobiological Updated

D. Chaplin, P. Olive, R. Durand, 1987 .

Radiosensitization in vivo: a study with an homologous series of 2-nitroimidazoles.

G. Adams, I. Stratford, D. Chaplin, 1983, International journal of radiation biology and related studies in physics, chemistry, and medicine.

Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results.

G. Jayson, G. Rustin, M. Zweifel, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The influence of microenvironment on the cytotoxicity of TNF [symbol: see text] vitro.

D. Chaplin, L. Sampson, 1994, International journal of radiation oncology, biology, physics.

Oxygen and nitroreductase-dependent binding of AF-2 in spheroids and murine tumors.

D. Chaplin, P. Olive, 1986, International journal of radiation oncology, biology, physics.

Functionalized benzophenone, thiophene, pyridine, and fluorene thiosemicarbazone derivatives as inhibitors of cathepsin L.

D. Chaplin, B. Siim, M. L. Trawick, 2010, Bioorganic & medicinal chemistry letters.

Reduction of tumour blood flow by vasoactive drugs: a role in cancer therapy.

M. Horsman, D. Chaplin, B. Acker, 1989, Biomedica biochimica acta.

A prostacyclin-like substance in rat brain

D. Chaplin, K. Hillier, 2007 .

Synthesis and biological evaluation of a water-soluble phosphate prodrug salt and structural analogues of KGP94, a lead inhibitor of cathepsin L.

Zhe Shi, D. Chaplin, M. L. Trawick, 2017, Bioorganic & medicinal chemistry letters.

Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling combretastatin A-4 with application as a vascular disrupting agent.

R. Mason, D. Chaplin, E. Hamel, 2013, Journal of natural products.

Small-molecule inhibitors of cathepsin L incorporating functionalized ring-fused molecular frameworks.

D. Chaplin, M. L. Trawick, Jian-Guo Song, 2013, Bioorganic & medicinal chemistry letters.

Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.

G. Tozer, D. Chaplin, S. Hill, 1997, Cancer research.

Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management

B. Ky, Joan L. Walker, D. Chaplin, 2018, Gynecologic Oncology Research and Practice.

The development and use of vascular targeted therapy in ovarian cancer.

B. Monk, D. Chaplin, D. Chase, 2017, Gynecologic oncology.

Structure Guided Design, Synthesis, and Biological Evaluation of Novel Benzosuberene Analogues as Inhibitors of Tubulin Polymerization.

R. Mason, D. Saha, D. Chaplin, 2019, Journal of medicinal chemistry.

Design, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agents.

R. Mason, D. Chaplin, E. Hamel, 2016, Bioorganic & medicinal chemistry.

Development of synthetic methodology suitable for the radiosynthesis of combretastatin A-1 (CA1) and its corresponding prodrug CA1P.

D. Chaplin, S. Sharma, John J. Hall, 2009, Journal of natural products.

The effect of artificially induced ischemia on tumour cell survival.

M. Horsman, D. Chaplin, 1994, Advances in experimental medicine and biology.

Combretastatin A-4, an agent that displays selective toxicity towards tumour vasculature

G. Tozer, D. Chaplin, G. Pettit, 1997 .

Tumour blood flow changes induced by application of electric pulses.

M Cemazar, G Sersa, M. Čemažar, 1999, European journal of cancer.

Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia.

Zhe Shi, D. Chaplin, E. Hamel, 2017, Bioorganic & medicinal chemistry letters.

Synthesis and biochemical evaluation of benzoylbenzophenone thiosemicarbazone analogues as potent and selective inhibitors of cathepsin L.

Ashleigh L. Barnes, M. Horsman, D. Chaplin, 2015, Bioorganic & medicinal chemistry.

Can PDT be potentiated by immunotherapy?

Gorazd Krosl, David J. Chaplin, Mladen Korbelik, 1993, Other Conferences.

Photofrin uptake by murine macrophages.

M. Korbelik, D. Chaplin, G. Krosl, 1991, Cancer research.

Design, synthesis, biochemical, and biological evaluation of nitrogen-containing trifluoro structural modifications of combretastatin A-4.

D. Chaplin, G. Pettit, M. L. Trawick, 2008, Bioorganic & medicinal chemistry letters.

Regio- and stereospecific synthesis of mono-beta-d-glucuronic acid derivatives of combretastatin A-1.

D. Chaplin, B. Siim, M. L. Trawick, 2010, Journal of natural products.

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.

B Vojnovic, G M Tozer, M Cemazar, 2001, Cancer research.

Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

B Vojnovic, G M Tozer, B. Vojnovic, 1999, Cancer research.

Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents.

D. Chaplin, G. Pettit, M. L. Trawick, 2008, Journal of natural products.

Synthesis of dihydronaphthalene analogues inspired by combretastatin A-4 and their biological evaluation as anticancer agents.

R. Mason, D. Chaplin, Heling Zhou, 2018, MedChemComm.

Synthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3'-hydroxy-4'-methoxyphenyl)-3-(3″,4″,5″-trimethoxybenzoyl)-6-methoxyindole (OXi8006).

D. Chaplin, E. Hamel, M. L. Trawick, 2013, Bioorganic & medicinal chemistry.

Therapeutic Significance of Microenvironmental Factors

M. Trotter, M. Horsman, D. Chaplin, 2000 .

Potentiation of the tumor cytotoxicity of melphalan by vasodilating drugs.

D. Chaplin, P. Olive, B. Acker, 1989, International journal of radiation oncology, biology, physics.

Structural interrogation of benzosuberene-based inhibitors of tubulin polymerization.

R. Mason, D. Chaplin, E. Hamel, 2015, Bioorganic & medicinal chemistry.

Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.

Alejandro J. Ramirez, R. Mason, Zhe Shi, 2020, Journal of natural products.

Development of Vascular Disrupting Agents

D. Chaplin, G. Dougherty, 2010 .

Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents.

D. Chaplin, S. Hill, C. Parkins, 1996, The British journal of cancer. Supplement.

Inhibition of nitric oxide synthase induces a selective reduction in tumor blood flow that is reversible with L-arginine.

G. Tozer, D. Chaplin, V. Prise, 1997, Cancer research.

The ability of nicotinamide to inhibit the growth of a C3H mouse mammary carcinoma.

J. Overgaard, M. Horsman, A. Khalil, 1995, Acta oncologica.

Modification of tumor blood flow: current status and future directions.

G M Tozer, G. Tozer, D. Chaplin, 1998, Seminars in radiation oncology.

The effect of therapy on tumour vascular function.

D. Chaplin, D J Chaplin, 1991, International journal of radiation biology.

Possible mechanisms for intermittent blood flow in the murine SCCVII carcinoma.

M. Trotter, D. Chaplin, P. Olive, 1991, International journal of radiation biology.

The use of blood flow modifiers to improve the treatment response of solid tumors.

J. Overgaard, M. Horsman, D. Chaplin, 1991, Radiotherapy and Oncology.

The use of fluorescent probes to identify regions of transient perfusion in murine tumors.

M. Trotter, D. Chaplin, R E Durand, 1989, International journal of radiation oncology, biology, physics.

Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models

R. Kerbel, E. Voest, R. Hoffman, 2009, Molecular Cancer Therapeutics.

The potentiation of radiation damage by nicotinamide in the SCCVII tumour in vivo.

J. Overgaard, M. Horsman, P. Wood, 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Synthesis of structurally diverse benzosuberene analogues and their biological evaluation as anti-cancer agents.

D. Chaplin, M. L. Trawick, R. Tanpure, 2013, Bioorganic & medicinal chemistry.

Regioselective synthesis of water-soluble monophosphate derivatives of combretastatin A-1.

D. Chaplin, E. Hamel, B. Siim, 2011, Journal of natural products.

Vascular Disrupting Agents in Cancer Therapy

C. Kanthou, G. Tozer, D. Chaplin, 2008 .

The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability.

K. Brindle, D. Beauregard, D. Chaplin, 2001, Cancer research.

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status.

K. Brindle, P. Thelwall, G. Adams, 1998, British Journal of Cancer.

Nicotinamide as a radiosensitizer in tumours and normal tissues: the importance of drug dose and timing.

J. Overgaard, M. Horsman, D. Chaplin, 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues.

M. Horsman, D. Chaplin, J M Brown, 1987, Radiation research.

Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4.

A. Boulares, D. Rosenthal, M. Smulson, 1998, Cancer research.

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.

G. Jayson, G. Rustin, M. Zweifel, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer

T. Ganesan, G. Rustin, P. Nathan, 2010, British Journal of Cancer.

Areviewandupdateof thecurrentstatusofthe vasculature-disabling agentcombretastatin-A4 phosphate(CA4P)

D. Chaplin, P. Walicke, D. Siemann, 2009 .

An update on the clinical development of drugs to disable tumor vasculature

D. Chaplin, D. Siemann, 2007, Expert opinion on drug discovery.

Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer

M. Horsman, D. Chaplin, D. Siemann, 2017, Cancer investigation.

Tumour radiosensitization by high-oxygen-content gases: influence of the carbon dioxide content of the inspired gas on PO2, microcirculatory function and radiosensitivity.

B Vojnovic, B. Vojnovic, D. Chaplin, 1998, International journal of radiation oncology, biology, physics.

Improved Treatment of Tumours in vivo by Combining the Bioreductive Drug RSU-1069, Hydralazine and Hyperthermia

J. Overgaard, M. Horsman, K. L. Christensen, 1990 .

Chemosensitizing AML cells by targeting bone marrow endothelial cells.

D. Purich, G. Walter, D. Chaplin, 2016, Experimental hematology.

Immune reaction induced by X-rays and pions and its stimulation by schizophyllan (SPG).

B. Palcic, A. Nishioka, D. Chaplin, 1996, The British journal of cancer. Supplement.

Examples of adjuvant treatment enhancing the antitumor effect of photodynamic therapy

Mladen Korbelik, Ivana Cecic, Jinghai Sun, 1999, Photonics West - Biomedical Optics.

An Amino-Benzosuberene Analogue That Inhibits Tubulin Assembly and Demonstrates Remarkable Cytotoxicity.

D. Chaplin, E. Hamel, M. L. Trawick, 2012, MedChemComm.

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors

S. Halford, P. Price, A. Padhani, 2012, Clinical Cancer Research.

The vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts.

R. Mason, D. Chaplin, Li Li, 2015, Cancer letters.

Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.

R. Pedley, D. Chaplin, R. Begent, 2001, Cancer research.

Vascular‐targeting therapies for treatment of malignant disease

M. Horsman, D. Chaplin, D. Siemann, 2004, Cancer.

Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts

M A Konerding, J. Denekamp, M. Presta, 1999, British Journal of Cancer.

DNA damage and repair in tumour and non-tumour tissues of mice induced by nicotinamide.

Y. Sheng, R. Pero, A. Olsson, 1996, British Journal of Cancer.

Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging

F. Howe, J. Griffiths, S. Robinson, 1999, NMR in biomedicine.

The effects of hyperoxic and hypercarbic gases on tumour blood flow

G. Rosner, M. Dewhirst, T. Secomb, 1999, British Journal of Cancer.

Hydralazine-induced tumor hypoxia: a potential target for cancer chemotherapy.

D. Chaplin, 1990, Journal of the National Cancer Institute.

Modification of blood flow in the HSN tumour and normal tissues of the rat by the endothelin ETB receptor agonist, IRL 1620

G. Tozer, D. Chaplin, V. Prise, 1999, International journal of cancer.

Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats.

N. Bodyak, P. Kang, N. Hurst, 2009, Vascular pharmacology.

The interaction between RSU-1069, hydralazine and hyperthermia in a C3H mammary carcinoma as assessed by tumour growth delay.

J. Overgaard, M. Horsman, D. Chaplin, 1988, Acta oncologica.

Effect of nitro-L-arginine on blood flow, oxygenation and the activity of hypoxic cell cytotoxins in murine tumours.

J. Overgaard, M. Horsman, P. Wood, 1996, The British journal of cancer. Supplement.

Tumor blood flow modifying effect of electrochemotherapy with bleomycin.

D Miklavcic, M Cemazar, G Sersa, 1999, Anticancer research.

Vascular response of tumour and normal tissues to endothelin‐1 following antagonism of ETA and ETB receptors in anaesthetised rats

G. Tozer, D. Chaplin, V. Prise, 1997, International journal of cancer.

Reduced capacity of tumour blood vessels to produce endothelium-derived relaxing factor: significance for blood flow modification.

M. Stratford, G. Tozer, D. Chaplin, 1996, British Journal of Cancer.

Effect of Endothelin‐1 and Sarafotoxin S6c on Blood Flow in a Rat Tumor

G. Tozer, D. Chaplin, V. Prise, 1995, Journal of cardiovascular pharmacology.

Use of a carbocyanine dye as a marker of functional vasculature in murine tumours.

P. Olive, M. Trotter, D. Chaplin, 1989, British Journal of Cancer.

Effect of nicotinamide on the microregional heterogeneity of oxygen delivery within a murine tumor.

M. Trotter, M. Horsman, D. Chaplin, 1990, Journal of the National Cancer Institute.

Influence of hypoxia and tumour-conditioned medium on endothelial cell adhesion molecule expression in vitro.

D. Chaplin, M. Watts, C. Parkins, 2002, Anticancer research.

Vascular Disrupting Agents

D. Chaplin, D. Siemann, G. Dougherty, 2007 .

A multicenter, open-label phase Ib/II study to assess the safety and clinical activity of intravenous combretastatin A1 diphosphate (OXi4503) as monotherapy in subjects with primary or secondary hepatic tumor burden.

M. Brown, M. Millward, P. Mainwaring, 2010 .

Potentiation of RSU-1069 tumour cytotoxicity by 5-hydroxytryptamine (5-HT).

D. Chaplin, 1986, British Journal of Cancer.

The comparative effects of the NOS inhibitor, Nomega-nitro-L-arginine, and the haemoxygenase inhibitor, zinc protoporphyrin IX, on tumour blood flow.

G. Tozer, D. Chaplin, R. Motterlini, 1998, International journal of radiation oncology, biology, physics.

Studies on the protection against misonidazole-induced toxicity by antiinflammatory agents.

D. Chaplin, B. C. Millar, S. Jinks, 1983, Advances in prostaglandin, thromboxane, and leukotriene research.

Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes.

P. Hoskin, M. Leahy, D. Chaplin, 1996, The British journal of cancer. Supplement.

Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide

G. Tozer, D. Chaplin, S. Hill, 2000, British Journal of Cancer.

Effect of different stopping volumes of clinical pion beams at TRIUMF on the mouse small intestine.

L. Skarsgard, D. Chaplin, G. Lam, 1989, Radiation research.

In Vitro and in Vivo Studies of the TRIUMF Pion Therapy Beam

B. Palcic, L. Skarsgard, J. Denekamp, 1985 .

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.

A. Harris, G. Rustin, D. Link, 2009, Cancer research.

Preclinical evaluation of the novel hypoxic marker 99mTc-HL91 (Prognox) in murine and xenograft systems in vivo.

D. Chaplin, S. Hill, D J Chaplin, 1998, International journal of radiation oncology, biology, physics.

Combination therapy of pions and SPG (Sonifilan, Schizophyllan), a biological response modifier for mouse tumor systems.

D. Chaplin, G. Lam, G. Goodman, 1990, International journal of radiation oncology, biology, physics.

Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry.

D. Chaplin, S. Hill, M. Saunders, 1996, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The response of mouse epidermis to fractionated doses of pi mesons.

L. Skarsgard, J. Denekamp, D. Chaplin, 1987, International journal of radiation oncology, biology, physics.

Pions and pig skin: preclinical evaluation of RBE for early and late damage.

L. Skarsgard, J. Denekamp, D. Chaplin, 1986, International journal of radiation oncology, biology, physics.

Preclinical evaluation of pions in vivo: experience at TRIUMF.

L. Skarsgard, J. Denekamp, D. Chaplin, 1990, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Ischemia reperfusion injury in tumors: the role of oxygen radicals and nitric oxide.

M. Stratford, D. Chaplin, S. Hill, 1995, Cancer research.

Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging

F. Howe, J. Griffiths, S. Robinson, 1999, NMR in biomedicine.

The effect of artificially induced hyperglycemia on the radiation response of the Lewis lung and EMT6 tumor models.

M. Horsman, D. Chaplin, 1988, International journal of radiation biology.

Design, synthesis, and biological evaluation of potent thiosemicarbazone based cathepsin L inhibitors

D. Chaplin, B. Siim, M. L. Trawick, 2010, Bioorganic & Medicinal Chemistry Letters.

Involvement of oxygen free radicals in ischaemia-reperfusion injury to murine tumours: role of nitric oxide.

M. Stratford, D. Chaplin, M. F. Dennis, 1998, Free radical research.

Biochemical and physiological changes induced by nicotinamide in a C3H mouse mammary carcinoma and CDF1 mice.

P. Kristjansen, J. Overgaard, M. Horsman, 1992, International journal of radiation oncology, biology, physics.

Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours.

H Black, D. Chaplin, P. Olive, 1985, British Journal of Cancer.

Cytotoxic effect of tumour necrosis factor -alpha on sarcoma F cells at tumour relevant oxygen tensions.

M. Horsman, A. Khalil, D. Chaplin, 1995, Acta oncologica.

Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L.

M. Horsman, D. Chaplin, K. Pinney, 2012, European journal of medicinal chemistry.

Enhancement of chlorambucil cytotoxicity by combination with flavone acetic acid in a murine tumour.

D. Chaplin, C. Parkins, J. A. Chadwick, 1994, Anticancer research.